Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EMERYVILLE, Calif., Oct. 21, 2021 /PRNewswire/ --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Scott Myers to its Board of Directors.

Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman

EMERYVILLE, Calif., Oct. 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, will report third quarter 2021 financial results on Thursday, November 4, 2021, after the U.S. financial markets close.

Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021

Ocugen, Inc.

These COVID-19 vaccine developers are all moving in response to strong late-stage results for Valneva's VLA2001.

Why Shares of Dynavax Technologies, Ocugen, and Valneva Are on the Move Today

EMERYVILLE, Calif., Oct. 18, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Valneva SE reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavax's CpG 1018® adjuvant.

COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial

Dynavax developed CpG 1018 many years ago. The coronavirus pandemic gave CpG 1018 a vast market to tap.

Dynavax And TLR Biology: Long-Delayed But Outstanding Success

EMERYVILLE, Calif., Oct. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, and the U.S. Department of Defense (DOD) today announced Dynavax has executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018®.

Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax's CpG 1018 Adjuvant

A possible oral COVID-19 treatment is weighing on the shares of vaccine markers like Dynavax today.

Why Dynavax Technologies Stock Is Sliding Today

EMERYVILLE, Calif., Sept. 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that it will participate in the following investor conferences.

Dynavax to Present at Upcoming Investment Conferences

It's definitely not a showstopper for the biotech or its CpG 1018 adjuvant.

How Will Valneva's COVID Vaccine Setback Impact Dynavax?

Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.

Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data

The stock price of Dynavax Technologies Corporation (NASDAQ: DVAX) increased by over 25% today. This is why it happened.

DVAX Stock: Why It Significantly Increased Today

Biopharmaceutical concern Dynavax Technologies Corporation (NASDAQ:DVAX) is up 33.9% to trade at $19.90 this afternoon.

Surging Dynavax Stock Could Soar Even Higher

Today, some impressive vaccine-related news has sent Dynavax and shares of DVAX stock significantly higher as investors pile in. The post DVAX Stock: What Is the Covid-19 News Lifting Dynavax Today?

DVAX Stock: What Is the Covid-19 News Lifting Dynavax Today?

A COVID-19 vaccine candidate that employs the company's adjuvant technology produced positive clinical trial results.

Why Dynavax Technologies Stock Is Soaring Today

Clover Biopharmaceuticals has reported positive data for their COVID-19 vaccine candidate, SCB-2019, which achieved the primary and secondary efficacy endpoints in SPECTRA Phase 2/3 clinical trial. The protein-based vaccine is adjuvanted with Dynavax Technologies Corporation's (NASDAQ: DVAX) CpG 1018 adjuvant.

Why Are Dynavax Technologies Shares Skyrocketing Today?

EMERYVILLE, Calif., Sept. 22, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Clover Biopharmaceuticals (Clover) reported positive data for their protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) adjuvanted with Dynavax's CpG 1018 adjuvant, which achieved the primary and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 2/3 clinical trial that enrolled over 30,000 participants.

COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial

GlaxoSmithKline

Inovio Pharmaceuticals

Novavax

Sanofi

Their vaccines could be late to the party. But the stocks might still be big winners.

5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch

Saint- Herb lain (Franc e ) , September 14 , 2021 – Valneva SE, a specialty vaccine company, today announced that it has completed recruitment of the initial cohort of elderly participants in Valneva's Phase 3 trial, VLA2001-304, of its inactivated COVID-19 vaccine candidate, VLA2001.

Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine

A lost supply agreement for a partner's COVID-19 vaccine is hurting the biotech's shares today.

Why Dynavax Technologies Stock Is Sinking Today

Dynavax Technologies Corp (NASDAQ: DVAX) is trading lower after the company announced Valneva SE (NASDAQ: VALN) received a termination notice from the United Kingdom government in relation to Valneva's supply agreement for its COVID-19 vaccine candidate, VLA2001. Valneva said it intends to continue clinical development of VLA2001, which is currently in Phase 3 trials.

Why Dynavax Shares Are Trading Lower Today

Apple

Alibaba

BioNTech SE

iShares MSCI Emerging Markets ETF

KraneShares CSI China Internet ETF

iShares MSCI China ETF

Netflix

NetEase

NXP Semiconductors

Pfizer

Invesco QQQ

SPDR S&P 500 ETF Trust

Valneva SE

Chinese regulators continue to apply pressure on the country's biggest tech companies, this time reportedly looking to split up Alibaba (NYSE:BABA) founder Jack Ma's Alipay. Beijing is pushing for Alipay to create a separate app for its loan business.

China Crackdown Continues

EMERYVILLE, Calif., Sept. 13, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Valneva SE has received a termination notice from the United Kingdom Government in relation to Valneva's supply agreement for its COVID-19 vaccine candidate, VLA2001.

Dynavax Provides Update on its COVID-19 Collaboration with Valneva

Saint- Herb lain (France ) , September 13 , 2021 – Valneva SE, a specialty vaccine company, today announced that it has received a termination notice from the UK Government (“HMG”) in relation to the Supply Agreement for its COVID-19 vaccine candidate, VLA2001. The contract provides HMG with the right to terminate. HMG has alleged that the Company is in breach of its obligations under the Supply Agreement, but the Company strenuously denies this.

Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Government

EMERYVILLE, Calif., Sept. 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C.

Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

One of the company's partners launched its COVID-19 vaccine in Taiwan.

News for Dynavax Technologies Stock (DVAX)